“Early detection saves lives” is one of the most repeated phrases in medicine, and it is true — for some cancers, in some people, at some ages. It is also, quietly, not true for others, and the gap between those two facts is where most “how to detect cancer early” content on the internet gets it wrong. Some articles imply that more scanning always helps. Others swing the other way and imply screening is a scam. Neither is accurate, and the actual answer changes completely depending on which cancer you’re asking about.
This is a cancer-by-cancer guide to what genuinely works, graded against the same evidence standards we use everywhere else on this site — including two findings that go against what most people assume: for one common cancer, the guideline recommendation is to actively avoid screening average-risk people, and for another widely feared cancer, no general-population screening test exists at all.
Key takeaways
- Only four cancers have general-population screening tests with strong, guideline-backed evidence behind them: breast, colorectal, cervical, and lung cancer (in long-term heavy smokers).
- USPSTF recommends against ovarian cancer screening in average-risk women — its strongest form of a negative recommendation — after the largest trial ever run on the question, following over 200,000 women, found no significant reduction in deaths.
- There is no recommended screening test for pancreatic cancer in the general population; surveillance exists only for a narrow group with specific inherited genetic mutations or strong family history.
- AI-powered mole-checking apps have been shown in published research to flag far more lesions as suspicious than dermatologists do, and most dermatologists surveyed don’t consider them clinically reliable.
- “Finding more cancer” and “saving more lives” are not automatically the same thing — a distinction that gets lost in most popular coverage of this topic.
Quick Answer: What’s Actually Screenable, by Cancer Type
| Cancer | General-population screening test? | Who it’s for | Evidence grade |
|---|---|---|---|
| Breast | Yes — mammography | Women 40–74, biennial | Grade B |
| Colorectal | Yes — colonoscopy, stool-based tests, or CT colonography | Adults 45–75 | Grade A (50–75), Grade B (45–49) |
| Cervical | Yes — Pap smear and/or HPV testing | Women 21–65 | Grade A |
| Lung | Yes, but narrow — low-dose CT | Adults 50–80 with 20+ pack-year smoking history, current or quit within 15 years | Grade B |
| Prostate | Individualized — PSA blood test, MRI-first triage increasingly preferred | Men 55–69, shared decision-making | Grade C |
| Skin | Self-exam plus dermatologist visits, no population-wide screening program | Everyone, more frequently for high-risk individuals | Not formally graded by USPSTF; supported by specialty guidelines |
| Pancreatic | No — except for a narrow genetic high-risk group | Confirmed BRCA1/2, CDKN2A, or strong family history only | No general screening recommended |
| Ovarian | No — USPSTF recommends against screening average-risk women | N/A for average risk | Grade D (recommended against) |
Not sure which of these actually applies to you? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers, graded against USPSTF and other major guidelines. Take the Fit Check →
The Cancers With Real, Guideline-Backed Screening
Breast cancer
Mammography is the best-studied cancer screening test in existence, and USPSTF updated its guidance in 2024 to recommend biennial screening starting at age 40 for average-risk women, continuing through age 74 — a change from its earlier stance, which left the decision more open for women in their 40s. This is one of the clearest wins in cancer screening: decades of randomized trial data support real mortality reduction from regular mammography in this age range.
Colorectal cancer
Screening starts at 45 for average-risk adults and can take several forms: colonoscopy every 10 years, annual stool-based tests, or CT colonography, among other options. The evidence is strongest (Grade A) for ages 50 to 75, with slightly less certainty (Grade B) for the newer 45-to-49 recommendation. Colonoscopy has the added advantage of being able to remove precancerous polyps during the same procedure that finds them.
Cervical cancer
Screening with Pap smears, HPV testing, or both, starting at 21 and continuing through 65, is one of the oldest and most successful cancer screening programs in modern medicine, credited with a dramatic decline in cervical cancer rates and deaths since it became widespread.
Lung cancer — but only for a specific group
Low-dose CT screening genuinely reduces lung cancer deaths, but the benefit is real for a narrowly defined population: adults 50 to 80 with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years. Applied to that group, USPSTF concluded the benefits clearly outweigh the harms. Applied to a lifelong nonsmoker, the same scan offers essentially none of the benefit and all of the downside — radiation exposure and a real chance of a false alarm.
The Cancers Where “Early Detection” Gets More Complicated
Prostate cancer
This is the clearest example of screening science actually changing in real time. USPSTF’s current guidance for PSA blood testing is Grade C — an individualized decision for men 55 to 69, made together with a doctor, rather than a blanket recommendation — and it recommends against screening entirely for men 70 and older.
What’s changed more recently is what happens after an elevated PSA result. The landmark PRECISION trial, published in the New England Journal of Medicine, found that using MRI to triage men before biopsy — rather than proceeding straight to a standard biopsy — led to fewer men undergoing biopsy at all, more detection of clinically significant cancers, and meaningfully less overdetection of slow-growing cancers that would never have caused harm. MRI-first triage is now the standard first step in the UK and increasingly in the US, specifically because it addresses prostate cancer’s biggest historical problem: PSA-driven biopsies that found a lot of cancer that didn’t need to be found.
Skin cancer
There’s no formal population-wide screening program for skin cancer, but that doesn’t mean nothing works. Regular self-exams using the ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter over 6mm, Evolving appearance) combined with periodic dermatologist visits — more frequent for people with many moles, fair skin, or a personal or family history of skin cancer — remain the practical standard.
Where the evidence gets shakier is the newer wave of AI-powered mole-checking apps. A study published in The BMJ tested a CE-certified smartphone app against dermatologists and convolutional neural networks on more than 1,200 pigmented skin lesions, and found the app flagged a significantly higher number of lesions as high-risk than dermatologists did — the kind of over-flagging that, if acted on, would lead to a clinically meaningful number of unnecessary excisions. Only 8.8% of participating dermatologists considered the app reliable enough for clinical evaluation. That doesn’t make these apps worthless as a reminder to go get a mole checked by an actual dermatologist — it makes them a poor substitute for one.
Pancreatic cancer
This is the cancer most people asking “how do I catch cancer early” are quietly afraid of, and it’s also the one with the most sobering honest answer: there is no recommended screening test for pancreatic cancer in the general population. It’s rare enough, and current imaging isn’t sensitive enough at an early enough stage, that population-wide screening hasn’t been shown to help and isn’t recommended by any major guideline body.
Surveillance does exist, but only for a specific high-risk group defined by the International Cancer of the Pancreas Screening (CAPS) Consortium: carriers of certain inherited mutations (including BRCA1, BRCA2, PALB2, ATM, and CDKN2A) with a first-degree relative who had pancreatic cancer, or people from a family with multiple relatives affected by the disease. For that specific group, surveillance with a combination of endoscopic ultrasound and MRI/MRCP — not CT — typically starts between ages 40 and 50. For everyone else, the current honest answer is that there isn’t yet a reliable way to catch this specific cancer early through screening alone.
Ovarian cancer
This is the single most counterintuitive entry on this list, and the one most likely to surprise people who assume more testing is always better. USPSTF’s recommendation on ovarian cancer screening for average-risk, asymptomatic women is Grade D — its strongest category of actively recommending against a test, not just declining to endorse it.
The evidence behind that recommendation is about as rigorous as cancer screening research gets. UKCTOCS, the largest trial ever conducted on this question, randomized over 200,000 postmenopausal women in the UK to annual CA-125 blood testing, transvaginal ultrasound, or no screening, and found no significant reduction in ovarian and tubal cancer deaths in either screened group, even after long-term follow-up. A separate large US trial, PLCO, reached a similar conclusion, including in extended follow-up analyses years later. Meanwhile, the screening tests produced real false positives — close to 10 to 12% of women screened in the first round of UKCTOCS had a false-positive result, some of whom went on to unnecessary surgery. Screening remains a reasonable conversation to have for women with a known high-risk mutation (like BRCA1 or BRCA2) or strong family history — but for the average woman with no symptoms, the guideline-backed answer is genuinely “don’t.”
Why “Catch It Early” Isn’t Always Simple
None of this is really about screening being good or bad — it’s about a statistical trap that’s easy to miss even with good intentions.
Finding more cancer is not automatically the same thing as saving more lives. This is the single most important, least understood idea in cancer screening, and thyroid cancer is the clearest real-world proof of it. When South Korea rolled out widespread ultrasound screening as part of a general health check program in the 2000s, thyroid cancer diagnoses increased roughly fifteen-fold over about two decades — one of the fastest rises in cancer incidence ever recorded anywhere. Thyroid cancer deaths, over that same period, stayed essentially flat. The extra diagnoses were overwhelmingly small, slow-growing tumors that would likely never have caused a symptom or a death if left undetected — but once found, they were treated, often with surgery and its associated risks and complications, for a disease that in most cases would never have needed treatment at all. This is overdiagnosis in its starkest, most measurable form.
The math of screening only works when three things line up: the cancer needs to be common enough that screening a large population is worthwhile, detectable early enough that finding it actually changes the outcome, and slow-growing enough on average that catching it early beats catching it late — but not so uniformly slow-growing that most cases would never have caused harm anyway. Breast, colorectal, cervical, and lung cancer (in heavy smokers) thread that needle. Ovarian cancer, per the trial data above, apparently doesn’t — it may simply progress too fast, or start causing symptoms too early relative to when screening tests can reliably catch it, for annual screening to move the needle on death rates.
The fear of missing something outweighs the fear of a false alarm, psychologically — even when the statistics point the other way. This is the same pattern we’ve written about elsewhere on this site regarding whole-body MRI and general health checkups: a scan that finds nothing feels like proof of health, and a scan you didn’t get feels like an unquantified risk hanging over you, even when a rigorous 200,000-person trial says that specific test doesn’t reduce your risk of dying. That asymmetry is exactly why “USPSTF recommends against this screening” is such a hard message to hear, and such an easy one for direct-to-consumer testing companies to quietly route around.
What About Full-Body MRI and Multi-Cancer Blood Tests?
If the cancer-by-cancer picture above feels incomplete for your situation — especially if you’re worried about a cancer type with no guideline-backed screening test — you’ve likely already encountered the two products positioned as the answer: whole-body MRI and multi-cancer early detection (MCED) blood tests like Galleri. Both deserve their own full treatment, which we’ve given them elsewhere on this site rather than repeating here.
The short version: whole-body MRI finds a confirmed cancer in roughly 1 to 2 out of every 100 asymptomatic people scanned, against a much higher rate of incidental findings that trigger follow-up for something that, most of the time, isn’t cancer — covered in full in our evidence review of preventive scans and our comparison of specific full-body MRI providers. MCED blood tests are a genuinely interesting complement specifically because they target cancers like pancreatic and ovarian that have no screening test of their own — but sensitivity for early-stage disease is still their weakest point, and no MCED test has been shown to reduce cancer deaths in a randomized trial yet, which we cover in detail in our dedicated MCED evidence review.
The Bottom Line
There is no single answer to “how do I detect cancer early” — there are eight different answers, one per major cancer type, and they range from “yes, and it’s extremely well proven” (breast, colorectal, cervical) to “not really, and please don’t” (ovarian, for average-risk women) to “not yet, unless you’re in a specific high-risk group” (pancreatic). The honest, useful version of this question isn’t “what scan should I get” — it’s “which of these eight categories actually applies to me, given my age, sex, and risk factors,” which is a very different, much more answerable question.
Frequently Asked Questions
What is the best way to detect cancer early?
It depends entirely on which cancer you’re asking about — there is no single best way. For breast, colorectal, lung (in heavy smokers), and cervical cancer, guideline-backed screening tests exist with decades of trial evidence behind them. For pancreatic and ovarian cancer, no general-population screening test has been shown to help, and for ovarian cancer specifically, USPSTF recommends against screening average-risk women entirely. Matching the right test to the right cancer, at the right age, is the actual answer — not a single universal scan.
How can I detect cancer early if there’s no symptom?
For the cancers with proven screening tests (breast, colorectal, cervical, and lung cancer in heavy smokers), getting screened on the recommended schedule is how it’s done — these tests are specifically designed to find cancer before symptoms appear. For cancers without a general-population screening test, like pancreatic and ovarian cancer, the honest answer is that early, asymptomatic detection isn’t currently reliably possible for the average-risk person, which is why family history and genetic risk assessment matter more for these specific cancers.
Is there a screening test for pancreatic cancer?
Not for the general population — no screening test has been shown to reduce pancreatic cancer deaths in average-risk adults, and none is recommended by USPSTF or major guideline bodies. Surveillance with MRI/MRCP and endoscopic ultrasound is recommended, but only for a specific high-risk group: people with certain inherited genetic mutations (like BRCA1, BRCA2, or CDKN2A) or a strong family history of pancreatic cancer, typically starting between ages 40 and 50.
Should women get ovarian cancer screening?
For women at average risk with no symptoms, USPSTF recommends against ovarian cancer screening (Grade D, its strongest form of not recommending a test). The largest trial ever run on this question, UKCTOCS, followed over 200,000 women and found no significant reduction in ovarian cancer deaths from annual CA-125 blood testing or transvaginal ultrasound, while producing real false-positive rates. Screening remains reasonable to discuss for women with a known high-risk genetic mutation or strong family history.
Are AI mole-checking apps accurate for skin cancer?
Less than their marketing suggests. A study published in The BMJ found a CE-certified AI mole-checking app flagged significantly more lesions as high-risk than dermatologists did, and only 8.8% of participating dermatologists considered the app reliable for clinical evaluation. These apps may have a role in reminding people to get a suspicious mole checked, but they are not a substitute for an in-person dermatologist exam.
Is a full-body MRI a good way to detect cancer early?
For the average person with no symptoms or high-risk family history, the evidence is currently thin — published detection rates for confirmed cancer in asymptomatic people run around 1% to 2%, against a much higher rate of incidental findings that require follow-up. We cover this in detail in our full evidence review of whole-body MRI and our comparison of specific providers.
What blood tests can detect cancer early?
Multi-cancer early detection (MCED) blood tests like Galleri are designed to screen for a shared cancer signal across dozens of cancer types from one blood draw, and are marketed for adults 50 and older. Sensitivity is strongest for late-stage cancers and weakest for stage I disease — as low as 12% to 20% for some cancer types — which we cover in full in our dedicated evidence review of MCED tests.
What’s the difference between screening and diagnosis?
Screening looks for signs of cancer in people with no symptoms, using tests proven (for a handful of cancers) to catch disease early enough to change the outcome. Diagnosis is what happens after a screening test is positive, or after a person develops symptoms — further, more invasive testing (like a biopsy) to confirm or rule out cancer. A screening test result is never itself a cancer diagnosis.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Screening recommendations depend on your individual age, sex, risk factors, and family history — always consult a clinician before making decisions about cancer screening or your health. See our Methodology page for how we research and grade the evidence behind claims like these.
Sources
- U.S. Preventive Services Task Force. Final Recommendation Statement: Breast Cancer Screening, 2024.
- U.S. Preventive Services Task Force. Colorectal Cancer: Screening.
- U.S. Preventive Services Task Force. Cervical Cancer: Screening.
- U.S. Preventive Services Task Force. Lung Cancer: Screening.
- U.S. Preventive Services Task Force. Prostate Cancer: Screening.
- U.S. Preventive Services Task Force. Ovarian Cancer: Screening.
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (PRECISION). New England Journal of Medicine, 2018;378:1767–1777.
- Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet, and extended follow-up analyses published via PMC.
- Buys SS, Partridge E, Black A, et al. Ovarian cancer screening in the PLCO randomized controlled trial: extended mortality results with median 15-year follow-up. PubMed, 2016.
- Goggins M, Overbeek KA, Canto MI, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Johns Hopkins University.
- Sangers TE, et al. Over-Detection of Melanoma-Suspect Lesions by a CE-Certified Smartphone App. Published research summarized via PMC and The BMJ.
- ScanGlean. Preventive Health Scans and Longevity Clinics, Explained.
- ScanGlean. Multi-Cancer Early Detection Blood Tests, Explained.
- ScanGlean. Prenuvo vs Neko Health vs SimonMed vs Ezra: Full-Body MRI Compared.